Author:
Thuillier Philippe,Bourhis David,Metges Jean Philippe,Le Pennec Romain,Amrane Karim,Schick Ulrike,Blanc-Beguin Frédérique,Hennebicq Simon,Salaun Pierre-Yves,Kerlan Véronique,Karakatsanis Nicolas,Abgral Ronan
Abstract
AbstractTo present the feasibility of a dynamic whole-body (DWB) 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors (WD-NETs). Sixty-one patients who underwent a DWB 68Ga-DOTATOC-PET/CT for a histologically proven/highly suspected WD-NET were prospectively included. The acquisition consisted in single-bed dynamic acquisition centered on the heart, followed by the DWB and static acquisitions. For liver, spleen and tumor (1–5/patient), Ki values (in ml/min/100 ml) were calculated according to Patlak's analysis and tumor-to-liver (TLR-Ki) and tumor-to-spleen ratios (TSR-Ki) were recorded. Ki-based parameters were compared to static parameters (SUVmax/SUVmean, TLR/TSRmean, according to liver/spleen SUVmean), in the whole-cohort and according to the PET system (analog/digital). A correlation analysis between SUVmean/Ki was performed using linear and non-linear regressions. Ki-liver was not influenced by the PET system used, unlike SUVmax/SUVmean. The regression analysis showed a non-linear relation between Ki/SUVmean (R2 = 0.55,0.68 and 0.71 for liver, spleen and tumor uptake, respectively) and a linear relation between TLRmean/TLR-Ki (R2 = 0.75). These results were not affected by the PET system, on the contrary of the relation between TSRmean/TSR-Ki (R2 = 0.94 and 0.73 using linear and non-linear regressions in digital and analog systems, respectively). Our study is the first showing the feasibility of a DWB 68Ga-DOTATOC-PET/CT acquisition in WD-NETs.
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Krenning, E. P. et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716–731 (1993).
2. Barrio, M. et al. The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. J. Nucl. Med. 58, 756–761 (2017).
3. Graham, M. M., Gu, X., Ginader, T., Breheny, P. & Sunderland, J. J. 68Ga-DOTATOC imaging of neuroendocrine tumors: A systematic review and metaanalysis. J. Nucl. Med. 58, 1452–1458 (2017).
4. Zaidi, H. & Karakatsanis, N. Towards enhanced PET quantification in clinical oncology. Br. J. Radiol. 91, 20170508 (2017).
5. Olsen IH, Langer SW, Federspiel BH, Oxbøl J, Loft A, Berthelsen AK, et al. 68Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. Am. J. Nucl. Med. Mol. Imaging. 6, 59–72 (2016).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献